Arcturus plans Phase II dosing of ARCT-2601 next quarter with top line data in 2H 2027 following 38-fold LUNAR 2.0 poten

Arcturus Q3 2026 earnings: ARCT-032 and ARCT-2601 updates, LUNAR 2.0 progress, and cash runway through 2028.